Scancell Reports Modi-1 Immune Responses Linked to Longer Progression-Free Survival
Scancell said immune responses to its Modi-1 therapy were linked to longer progression-free survival in a Phase 2 kidney cancer trial.
Scancell said immune responses to its Modi-1 therapy were linked to longer progression-free survival in a Phase 2 kidney cancer trial.